Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) – Analysts at Zacks Investment Research increased their Q3 2017 earnings per share estimates for Eyegate Pharmaceuticals in a research report issued to clients and investors on Tuesday. Zacks Investment Research analyst B. Marckx now expects that the specialty pharmaceutical company will post earnings per share of ($0.22) for the quarter, up from their previous estimate of ($0.35). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($0.97) EPS, FY2018 earnings at ($0.53) EPS and FY2019 earnings at ($0.42) EPS.

Eyegate Pharmaceuticals (NASDAQ:EYEG) last posted its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.39). Eyegate Pharmaceuticals had a negative net margin of 1,737.29% and a negative return on equity of 840.69%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.22 million.

ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/brokers-set-expectations-for-eyegate-pharmaceuticals-inc-s-q3-2017-earnings-eyeg.html.

Several other research firms have also commented on EYEG. Noble Financial reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Friday, May 19th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Eyegate Pharmaceuticals in a research note on Wednesday, June 14th.

Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.12 on Thursday. Eyegate Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $3.90. The stock’s 50 day moving average is $1.32 and its 200-day moving average is $1.86. The firm’s market capitalization is $12.18 million.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.